Tauros.com - Site Name Reserved
Geistlich Pharma AG Bahnhofstrasse 40 CH - 6110 Wolhusen
Phone: +41 41 492 55 55 Fax: +41 41 492 56 39 [email protected]
Optimal avoidance of infection and infection control are an absolute necessity when dealing with central vascular access devices (CVADs). Nevertheless, the incidence of CRBSI in Europe is 1.1 – 4.2 per 1000 catheter days despite the most varied preventive measures and the mortality of CRBSI is still between 5 and 25%. (1, 2, 3) The risk of CRBSI increases steadily depending on the duration of catheterisation. Already 24 hours after insertion of a CVAD, the vascular device can be coated with a biofilm. This
Tauros.com - Site Name Reserved